Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 SEK | +7.19% | +4.78% | -59.92% |
05-30 | Oncopeptides Issues Warrants Under Loan Deal with European Investment Bank | MT |
05-30 | Transcript : Oncopeptides AB, Q1 2024 Earnings Call, May 30, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 4.56 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-59.92% | 56.3M | C+ | ||
+16.13% | 122B | B+ | ||
+19.65% | 113B | B+ | ||
+18.31% | 26.49B | B | ||
-23.84% | 19.4B | B+ | ||
-18.70% | 16.24B | A- | ||
-19.28% | 15.4B | B | ||
-45.95% | 15.15B | A- | ||
+63.81% | 14.93B | C+ | ||
+1.94% | 13.52B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ONCO Stock
- Ratings Oncopeptides AB